Skip to content

Drama therapy to promote well-being and resilience in oncological care and aftercare with breast cancer patients.

Drama therapy to promote well-being and resilience in oncological care and aftercare with breast cancer patients.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00036673
Enrollment
45
Registered
2025-04-15
Start date
2025-09-19
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C50

Interventions

Group 1: The main aim of this study is to analyze the drama therapy intervention in the oncological care and follow-up care of breast cancer patients with regard to its mechanisms of action and effect

Sponsors

Universitätsklinikum Essen
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Breast cancer patients aged 18 to 75 who are in the care or follow-up care. Written consent to participate in the study must also have been given.

Exclusion criteria

Exclusion criteria: Participants who are excluded due to serious mental illnesses (such as schizophrenia or acute psychoses) or cognitive limitations that would make active participation in theater therapy difficult do not meet the inclusion criteria. Men with breast cancer are also excluded in order to examine a homogeneous group that can deal with the female aspect and consequences of the disease.

Design outcomes

Primary

MeasureTime frame
The primary outcome is 30 participants: data collection will take place from September 1st, 2025 to September 30th, 2026 and allows a sample size of around 30 participants during this period. The planned prospective study combines quantitative and qualitative methods to comprehensively evaluate the effectiveness of theater therapy in the oncological care and aftercare (a maximum of 15 years) of breast cancer patients. The study follows a pre-post design in which data are collected both before the start and after completion of the intervention. The quantitative component includes standardized surveys using the Hospital Anxiety and Depression Scale (HADS), Generalizied Anxiety Disorder Scale-7, Functional Assessment of Cancer Therapy – Breast (FACT-B) questionnaires, which enable measurement of anxiety, depression, self-concept and quality of life.

Secondary

MeasureTime frame
The secondary outcome is 13 months. After 13 month, the qualitative component will provide deeper insights into the subjective experiences of the patients through interviews and observation procedures. Combining both approaches allows objective data from the quantitative survey to be supplemented by the patients' individual perspectives in order to enable a comprehensive understanding of the effectiveness of drama therapy interventions.

Countries

Germany

Contacts

Public ContactSusann Kobus

Universitätsklinikum Essen

susann.kobus@uk-essen.de004920172386267

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026